Iron
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Iron
- Pharmacist Assessment Report
- Iron: Vitamin B12- and folate-independent constitutional megaloblastic anemia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Iron: Vitamin B12- and folate-independent constitutional megaloblastic anemia
One-Sentence Summary
Iron is an essential mineral given as replacement therapy and is currently marketed in Canada. The TxGNN model predicts it may be relevant to vitamin B12- and folate-independent constitutional megaloblastic anemia. No clinical trials or publications were found for this specific disease, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Vitamin B12- and folate-independent constitutional megaloblastic anemia |
| TxGNN Prediction Score | 0.9989 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 10 of 12; dormant: 2) |
| Number of DINs | 12 (marketed: 10) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for iron are not available in the data compiled for this report. Iron is a component of haemoglobin and of many enzymes, and iron products are widely used to replace iron.
The mechanistic fit here is weak. Megaloblastic anemia is mainly a disorder of DNA synthesis, usually linked to the vitamin B12 and folate pathways, rather than a problem of iron supply. A constitutional form that does not depend on B12 or folate points to an intrinsic metabolic defect. Iron would not be expected to correct such a defect.
The high score most likely reflects the model’s association between iron and anemia-related features, not a demonstrated therapeutic rationale. It should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
The approved indication text and dosage forms are not recorded in the local data. Main authorizations:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02502917 | PMS-IRON SUCROSE | Not recorded | Not recorded |
| 02243716 | VENOFER | Not recorded | Not recorded |
| 02546078 | FERINJECT | Not recorded | Not recorded |
| 02477777 | MONOFERRIC | Not recorded | Not recorded |
| 02243333 | FERRLECIT | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 79 interactions are recorded. Major interactions include dolutegravir and bictegravir, likely through reduced absorption of the antiviral when taken with iron. Moderate interactions include:
- Antibiotics: doxycycline, tetracycline, ciprofloxacin, cefdinir, chloramphenicol, delafloxacin.
- Bisphosphonates: alendronic acid, risedronic acid, ibandronate.
- Acid-lowering drugs: omeprazole, rabeprazole.
- Other: levodopa, deferiprone, magnesium oxide, sodium citrate, pancrelipase, baloxavir marboxil.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or publications, and the biology of this anemia points away from an iron-responsive mechanism. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Mechanism-of-action data for iron
- A literature review to find whether any case reports or studies link iron to this specific form of anemia
- Clinical or biochemical evidence that iron status plays a role in this condition
- Package insert warnings and contraindications from Health Canada, for the safety screening
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.